Fennec Pharmaceuticals (TSE:FRX) Insider Southpoint Capital Advisors Lp Sells 26,900 Shares

Key Points

• Southpoint Capital Advisors Lp sold a total of 66,114 shares of Fennec Pharmaceuticals over three days, impacting their ownership down to 4,050,314 shares.
• The recent sales occurred at average prices ranging from C$12.89 to C$13.23, totaling approximately C$877,774.36 in value.
• Fennec Pharmaceuticals' stock is currently priced at C$12.40 with a market capitalization of C$345.12 million, and has shown significant volatility with a one year low of C$5.65 and a high of C$13.83.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) insider Southpoint Capital Advisors Lp sold 26,900 shares of the company's stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of C$13.23, for a total value of C$355,887.00. Following the sale, the insider owned 4,050,314 shares of the company's stock, valued at C$53,585,654.22. This trade represents a 0.66% decrease in their position.

Southpoint Capital Advisors Lp also recently made the following trade(s):

• On Wednesday, October 8th, Southpoint Capital Advisors Lp sold 19,605 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$13.07, for a total value of C$256,237.35.
• On Thursday, October 9th, Southpoint Capital Advisors Lp sold 20,609 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$12.89, for a total value of C$265,650.01.

Fennec Pharmaceuticals Price Performance

TSE FRX traded down C$0.88 during trading on Friday, reaching C$12.40. The company's stock had a trading volume of 305 shares, compared to its average volume of 1,007. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The stock has a market capitalization of C$345.12 million, a PE ratio of -27.56 and a beta of 2.48. The firm has a fifty day moving average of C$12.18 and a 200 day moving average of C$10.71. Fennec Pharmaceuticals Inc. has a one year low of C$5.65 and a one year high of C$13.83.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.